Elranatamab

Published

dm+d

Unassigned

New Medicines

Triple class refractory multiple myeloma (MM)

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Bispecific monoclonal antibody, utilises anti-BCMA and anti-CD3 targeting arms paired through hinge mutation technology and placed in an IgG2A backbone.
The second most common haematological cancer, the incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Triple class refractory multiple myeloma (MM)
Subcutaneous injection